Bristol Still Rules Immuno-Oncology, But For How Long?

At $920m, sales for Opdivo still overshadow competitors, but market dynamics are set to change with introduction of Merck's Keytruda in first-line lung cancer and Roche's Tecentriq in second-line lung.

Bristol-Myers Squibb Co. reported strong third-quarter sales of $920m for its PD-1 inhibitor Opdivo, and also a rebound for its CTLA-4 inhibitor Yervoy, but the company now has to brace for its market share to be eroded by new competition.

Sales of $920m for Opdivo (nivolumab), up 202% from the same period in 2015, were slightly lower than the Street...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer